Zanzalintinib

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer

A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

Maintenance Zanzalintinib With Etoposide After HDCT in GCT